礼来 ( 1051.99, 29.97, 2.93%) 公司周四宣布，已推出一个平台，帮助雇主与提供低成本福利和综合性肥胖症管理项目的机构对接，旨在扩大其爆款减肥药 Zepbound 的可及性。

Eli Lilly (LLY) stock is in focus as the company launches Employer Connect to improve employee access to its obesity therapy Zepbound. Read more here.

Employers can use Lilly's platform to connect with different third-party program administrators that help manage obesity ...

March 5 (Reuters) - Eli Lilly said on Thursday it has rolled out a platform to help employers connect with organizations ...

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a ...

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly has officially launched Employer Connect, its direct-to-employer platform for its obesity medications, after ...

Lilly will make its Zepbound KwikPen (tirzepatide) – which delivers four weekly injections in one device – available through the programme at a cost of $449 across all doses for an individual patient, ...

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...